HIGHLIGHTS
- who: S. Gulia from the Department of Medical Oncology, Tata Memorial CentreIndia have published the article: Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis☆, in the Journal: (JOURNAL)
- what: As expected, collated trial-level analysis of combined data from four studies showed a significantly higher risk of several hematological and nonhematological toxicities in the PARPi group compared with placebo, which have to be considered in clinical decisions.
- how: The authors conducted and report here an . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.